The Journal of
Clinical Psychiatry

Movement Disorders

Educational Activity December 27, 2017

Epidemiology and Prevention of Tardive Dyskinesia

Christoph U. Correll, MD

J Clin Psychiatry 2017;78(9):e1426

Article Abstract

What risk factors suggest that patients are more likely to develop tardive dyskinesia (TD)? Can TD symptoms be prevented? Read this CME activity to learn about the prevalence, epidemiology, and prevention of these abnormal movements from an expert.

This CME activity is expired. For more CME activities, visit cme.psychiatrist.com.
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Save Save

Cite

Advertisement
GAM ID: sidebar-top

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Advertisement
GAM ID: sidebar-bottom

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens

View current Issue

Related Articles

Timely Diagnosis of Alzheimer Disease

Educational Activity

Timely Diagnosis of Alzheimer Disease

August 1, 2022

Early-stage diagnosis of Alzheimer disease leads to prompt treatment initiation and better patient QoL. Learn about new guidelines and technology advances and what’s on the horizon from authorities in...

Anna D. Burke, Danielle Goldfarb

Treatment of Early-Stage Alzheimer Disease

Educational Activity

Treatment of Early-Stage Alzheimer Disease

August 1, 2022

Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what,...

Anna D. Burke, Danielle Goldfarb

Educational Activity

Patient-Centered Care in Schizophrenia

March 23, 2021

Can a patient-centered approach to treatment be adopted for patients with schizophrenia? Can these patients take part in shared decision-making? Follow along as Dr Harvey shares his expertise.

Philip D. Harvey